10.1.01: Biotechnology Issue
Four analysts, two experts and top management from thirty-seven sector firms examine the Biotechnology sector in this special 179-page issue from The Wall Street Transcript.

    Online subscribers to the Healthcare sector also get
    Bear, Stearns & Company 14th Annual Healthcare Conference Issue & Healthcare Services Issue

  1. Biotechnology - In an in-depth (13,900 words) Analyst Roundtable, Peter Drake, Managing Director at Prudential Securities, Inc., Mary Ann Gray, Analyst focusing on both public and private healthcare investments at Federated Kaufman Fund, Michael King, Jr., Managing Director at Robertson Stephens and Elise Wang, Managing Director at Salomon Smith Barney, examine the outlook for the sector including new approaches to diseases, outlook for tools and technology companies and share specific stock recommendations.
  2. Searching for Executive Leadership in Biotechnology - In an in-depth (2,600 words) Expert Interview, Robert Hennessy, Managing Director at The Hennessy Group, examines the outlook for the sector.
  3. The Biotechnology Transformation - In an in-depth (2,500 words) Expert Interview, John Rhodes, Managing Partner for Pharmaceuticals and Life Sciences at Deloitte & Touche, examines the outlook for the sector.
  4. The TWST confidential Off-The-Record survey of management performance at nineteen sector firms asked market insiders about the ability of management teams to create shareholder value. Firms reviewed in Off-The-Record include:
    Amgen, Biogen, Celgene, Cephalon, Chiron, CV Therapeutics, Genentech, Human Genome Sciences, ILEX Oncology, Immunex, InterMune, Maxim Pharmaceuticals, Merck & Co., Millennium Pharmaceuticals, Pfizer, Pharmacia, POZEN, Transkaryotic Therapies, United Therapeutics
  5. CEO interviews (average 2,500 words). Top management of thirty-seven sector firms examine the outlook for their firm and the sector. Firms include:
    Allos Therapeutics, Applied Imaging, Biolex, Crucell NV, DrugAbuse Sciences, Genaera, Insmed, Introgen Therapeutics, NewBiotics, Omega Tech, Phytopharm, Restoragen, Aastrom Biosciences, Acacia Research, Advanced Viral Research, Applied Molecular Evolution, ARIAD Pharmaceuticals, AtheroGenics, BioTransplant, Cangene, Cephalon, CollaGenex Pharmaceuticals, Cortex Pharmaceuticals, Covance, CV Therapeutics, Dendreon, Forbes Medi-Tech, Harvard Bioscience, Hyseq, ILEX Oncology, Incara Pharmaceuticals, Inex Pharmaceutical, InterMune Pharmaceuticals, MediChem Life Sciences, Neurobiological Technologies, Ortec International, Zonagen
    6. ORDER THIS REPORT NOW! ONLY $175
    The report will be mailed first class. For fedex delivery, specify in the report details section and either include your fedex number or we will add $15 delivery charge. All sales are final.  Questions, call (212) 952-7433, or email us
    For immediate access online - click here to gain a password.
     
    Report details:  
    Your Name:  
    		 Company: 
    Address: 
    		 City: 
    State/Province:
    		 ZIP/Postal Code:
          		 Country:
    Phone:
    		 E-Mail:

    BILLING INFORMATION
    Credit Card
    		 Expiration Month/Year:
    Credit Card Number: 
     

     This Issue costs $175 - and is non-returnable.   

    The Wall Street Transcript does not endorse the views of any interviewee nor does it make stock recommendations.

     

Investors and Industry Execs.

The Wall Street Transcript has been used by investors and industry executives for 40 years as a unique tool for company and industry research.

TWST's roundtable panels and analyst interviews provide a sector perspective from Wall Street's best. 

Money manager interviews provide the view from the buy-side.

CEO interviews with hundreds of companies from the major sectors gives the company perspective right from the top.

Subscribe to a unique research tool for investors and industry executives. Call (212) 952 7433 or click here.

Sincerely,

Andrew Pickup
Publisher
HOME PRODUCTS SUBSCRIBE ABOUT ARCHIVE HOTLINE CONTACT EUROPE